Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Matinas BioPharma Holdings, Inc.MTNB · Entity 8443 | Director | April 30, 2025 | May 02, 2025 |
| TuHURA Biosciences, Inc./NVKTRA · Entity 6601 | Director | September 22, 2021 | September 23, 2021 |
| VivoSim Labs, INC.VIVS · Entity 8386 | Director · EXECUTIVE CHAIRMAN | January 27, 2026 | January 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Matinas BioPharma Holdings, Inc.
Report date April 30, 2025 · Filed May 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2035-04-30 | Direct | 11,600 |
Reported balance
After 2025-04-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-30 · Grant · Acquired 11,600 · Balance 11,600 F1: The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026.
TuHURA Biosciences, Inc./NV
Report date September 22, 2021 · Filed September 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2031-09-22 | Direct | 100,000 |
Reported balance
After 2021-09-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-09-22 · Grant · Acquired 100,000 · Balance 100,000 F1: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 22, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 22, 2021.
VivoSim Labs, INC.
Report date January 27, 2026 · Filed January 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,053 |
Reported balance
After 2026-01-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-27 · Grant · Acquired 15,000 · Balance 26,053 F1: The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. F2: Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.
F2: Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 27, 2026 Filed Jan 30, 2026 00:59 UTC | VivoSim Labs, INC. VIVS · Entity 8386 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-029888 · ownership.xml · nonDerivative · entry 1 Murphy Keith · CIK 0001536583 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,053 F1 · shares: The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. F2 · balance_after: Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split. Read SEC document |
| April 30, 2025 Filed May 2, 2025 17:19 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock Option (right to Buy) · Derivative | 11,600 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001641172-25-008425 · ownership.xml · derivative · entry 1 Murphy Keith · CIK 0001536583 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,600 Underlying: Common Stock · 11,600 shares Expires 2035-04-30 F1 · derivative.exercise_date: The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026. Read SEC document |
| August 07, 2024 Filed Aug 7, 2024 20:01 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantCommon Stock | 19,607 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-092719 · ownership.xml · nonDerivative · entry 1 Murphy Keith · CIK 0001536583 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,641 F1 · shares: The reported securities are represented by restricted stock units, which shall vest on the earlier of August 7, 2025 or the date of the annual meeting of stockholders held by the Issuer in 2025, subject to acceleration in the event of a change of control. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 20:01 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantOptions (right to buy) · Derivative | 143,731 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0000950170-24-092719 · ownership.xml · derivative · entry 3 Murphy Keith · CIK 0001536583 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,731 Underlying: Common Stock · 143,731 shares Expires 2034-08-05 F3 · derivative.exercise_date: The option becomes exercisable if, after the grant date, the closing sales price of the Common Stock, as reported on the Nasdaq Capital Market (based on a 90-trading day average), is at least $1.53 (subject to adjustment for stock splits), as confirmed by the Board of Directors or a committee thereof. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 20:01 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantOptions (right to buy) · Derivative | 574,923 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0000950170-24-092719 · ownership.xml · derivative · entry 2 Murphy Keith · CIK 0001536583 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 574,923 Underlying: Common Stock · 574,923 shares Expires 2034-08-05 F2 · derivative.exercise_date: The option vests in 3 equal annual installments on each of August 5, 2025, August 5, 2026 and August 5, 2027. Read SEC document |
| November 17, 2023 Filed Nov 17, 2023 23:37 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantCommon Stock | 19,607 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-064947 · ownership.xml · nonDerivative · entry 1 Murphy Keith · CIK 0001536583 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,034 F1 · shares: The reported securities are represented by restricted stock units, which shall vest on the earlier of November 17, 2024 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 02:10 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantCommon Stock | 19,607 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-035796 · doc4.xml · nonDerivative · entry 1 Murphy Keith · CIK 0001536583 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,427 F1 · shares: The reported securities are represented by restricted stock units, which shall vest on the earlier of November 9, 2023 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. Read SEC document |
| August 31, 2022 Filed Oct 20, 2022 10:05 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0000899243-22-033855 · doc4.xml · derivative · entry 1 Murphy Keith · CIK 0001536583 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-08-31 F1 · derivative.exercise_date: The option shares will vest on a quarterly basis over a period of forty-eight (48) months from August 31, 2022. Read SEC document |
| October 07, 2021 Filed Oct 12, 2021 22:00 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0000899243-21-039910 · doc4.xml · derivative · entry 3 Murphy Keith · CIK 0001536583 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-10-07 F3 · derivative.exercise_date: The option shares shall vest and become exercisable on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders. Read SEC document |
| October 07, 2021 Filed Oct 12, 2021 22:00 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0000899243-21-039910 · doc4.xml · derivative · entry 2 Murphy Keith · CIK 0001536583 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-10-07 F2 · derivative.exercise_date: The option becomes exercisable, if at all, if the 45-day moving average closing price of the Issuer's common stock on The Nasdaq Stock Market LLC exceeds $35.00 per share. Read SEC document |
| October 07, 2021 Filed Oct 12, 2021 22:00 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0000899243-21-039910 · doc4.xml · derivative · entry 1 Murphy Keith · CIK 0001536583 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-10-07 F1 · derivative.exercise_date: The option becomes exercisable, if at all, if the 45-day moving average closing price of the Issuer's common stock on The Nasdaq Stock Market LLC exceeds $30.00 per share. Read SEC document |
| September 22, 2021 Filed Sep 23, 2021 00:43 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0000905718-21-001227 · kintara_fm4sep222021.xml · derivative · entry 1 Murphy Keith · CIK 0001536583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-09-22 F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 22, 2021. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 21:46 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $10.27 | $0.00 |
DisclosureSEC source: 0000899243-21-010982 · doc4.xml · derivative · entry 4 Murphy Keith · CIK 0001536583 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-03-08 F4 · derivative.exercise_date: The option becomes exercisable, if at all, if the 45-day moving average closing price of Organovo Holdings, Inc.'s common stock on The Nasdaq Stock Market LLC exceeds $25.00 per share. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 21:46 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $10.27 | $0.00 |
DisclosureSEC source: 0000899243-21-010982 · doc4.xml · derivative · entry 3 Murphy Keith · CIK 0001536583 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-03-08 F3 · derivative.exercise_date: The option becomes exercisable, if at all, if the 45-day moving average closing price of Organovo Holdings, Inc.'s common stock on The Nasdaq Stock Market LLC exceeds $20.00 per share. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 21:46 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $10.27 | $0.00 |
DisclosureSEC source: 0000899243-21-010982 · doc4.xml · derivative · entry 2 Murphy Keith · CIK 0001536583 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2031-03-08 F2 · derivative.exercise_date: 25% of the option shares vest and become exercisable on March 8, 2022 and the remaining shares vest in 12 equal quarterly installments thereafter. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 21:46 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-010982 · doc4.xml · nonDerivative · entry 1 Murphy Keith · CIK 0001536583 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,320 F1 · shares: The reported securities are represented by restricted stock units, 25% of which shall vest on March 8, 2022 and the remaining shares vest in 12 equal quarterly installments thereafter. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 01:00 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000905718-20-000963 · kintara_fm4sep152020.xml · derivative · entry 1 Murphy Keith · CIK 0001536583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2030-09-15 F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 15, 2020. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 23:25 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $7.64 | $0.00 |
DisclosureSEC source: 0001209191-20-051052 · doc4.xml · derivative · entry 2 Murphy Keith · CIK 0001536583 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-09-15 F2 · derivative.exercise_date: The option shares vest and become exercisable over 12 equal quarterly installments measured from September 15, 2020. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 23:25 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $7.64 | $0.00 |
DisclosureSEC source: 0001209191-20-051052 · doc4.xml · derivative · entry 1 Murphy Keith · CIK 0001536583 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2030-09-15 F1 · derivative.exercise_date: 25% of the option shares vest and become exercisable on September 15, 2021 and the remaining shares vest in 12 equal quarterly installments thereafter. Read SEC document |
| September 15, 2020 Filed Dec 12, 2020 00:37 UTC Amendment | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $7.64 | $0.00 |
DisclosureSEC source: 0000899243-20-033636 · doc4a.xml · derivative · entry 1 Murphy Keith · CIK 0001536583 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-09-15 F1 · shares: As previously reported on a Form 4 filed on September 17, 2020 by the Reporting Person, the Reporting Person reported acquiring stock options to purchase 130,000 shares of common stock. However, Organovo Holdings, Inc. (the "Company") subsequently determined that stock options to purchase 65,000 shares of common stock under the Company's 2012 Equity Incentive Plan, as amended (the "Plan"), were not validly granted pursuant to the Plan because they exceeded the Plan limit on the number of stock options that may be granted to any one person during any calendar year. Accordingly, the attempted grant of these excess stock options was ineffective, and they were never granted to the Reporting Person. The Reporting Person is filing this amendment to report the correct amount of stock options acquired. F2 · derivative.exercise_date: 25% of the option shares vest and become exercisable on September 15, 2021 and the remaining shares vest in 12 equal quarterly installments thereafter. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 20:16 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | PurchaseCommon Stock | 181,010 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-20-023271 · ownership.xml · nonDerivative · entry 1 Murphy Keith · CIK 0001536583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,010 F1 · price: Received in exchange for 115,000 shares of Adgero Biopharmaceuticals Holdings, Inc. ("Adgero") common stock, par value $0.0001 per share, in connection with the completion of the merger (the "Merger"), on August 19, 2020 (the "Effective Date"), of Adgero Acquisition Corp., a subsidiary of the Issuer, with and into Adgero, pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 9, 2020. On the Effective Date, each share of Adgero common stock was converted automatically into the right to receive 1.5740 shares of the Issuer's common stock, par value $0.001 per share. Read SEC document |
| November 24, 2017 Filed Dec 4, 2017 14:00 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | PurchaseCommon Stock | 200,500 | $1.49 | $299,346.50 |
DisclosureSEC source: 0001536583-17-000002 · primary_doc.xml · nonDerivative · entry 2 Murphy Keith · CIK 0001536583 · Former affiliate last filing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,373,673 Read SEC document |
| November 22, 2017 Filed Dec 4, 2017 14:00 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | PurchaseCommon Stock | 135,000 | $1.50 | $201,960.00 |
DisclosureSEC source: 0001536583-17-000002 · primary_doc.xml · nonDerivative · entry 1 Murphy Keith · CIK 0001536583 · Former affiliate last filing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,173,173 Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 23:01 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 5,742 | $2.95 | $16,938.90 |
DisclosureSEC source: 0001209191-17-012853 · doc4.xml · nonDerivative · entry 1 Murphy Keith · CIK 0001536583 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,038,173 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1,831,454 shares of common stock underlying outstanding options held by Mr. Murphy; post-transaction Mr. Murphy continues to beneficially own or have a right to acquire 7,869,627 shares of common stock. Read SEC document |
| February 14, 2017 Filed May 9, 2017 22:03 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GiftCommon Stock | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-031051 · doc5.xml · nonDerivative · entry 1 Murphy Keith · CIK 0001536583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,019,173 F1 · kind: This transaction represents charitable contributions by the Reporting Person. F2 · balance_after: This number does not include 1,831,454 shares of common stock underlying outstanding options held by Mr. Murphy; post-transaction Mr. Murphy continues to beneficially own or have a right to acquire 7,850,627 shares of common stock. Read SEC document |
| February 09, 2017 Filed Feb 10, 2017 23:39 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | SaleCommon Stock | 25,000 | $3.68 | $92,035.00 |
DisclosureSEC source: 0001209191-17-009742 · doc4.xml · nonDerivative · entry 2 Murphy Keith · CIK 0001536583 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,043,915 F2 · kind: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $3.63 to $3.74. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F4 · balance_after: This number does not include 1,831,454 shares of common stock underlying outstanding options held by Mr. Murphy; post-transaction Mr. Murphy continues to beneficially own or have a right to acquire 7,875,369 shares of common stock. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 23:39 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Exercise / conversionWarrant · Derivative | 30,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001209191-17-009742 · doc4.xml · derivative · entry 3 Murphy Keith · CIK 0001536583 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2017-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Reporting Person exercised warrants to purchase 30,000 shares of the Issuer's common stock for $1.00 a share. The warrant would have expired by its terms if not exercised by the Reporting Person on February 8, 2017. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 23:39 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Exercise / conversionCommon Stock | 30,000 | $1.00 | $30,000.00 |
DisclosureSEC source: 0001209191-17-009742 · doc4.xml · nonDerivative · entry 1 Murphy Keith · CIK 0001536583 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · IRA Disclosed balance after: 6,068,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: The Warrants are held by the Equity Trust Co. Custodian FBO Keith Murphy IRA. Read SEC document |
| January 24, 2017 Filed Jan 25, 2017 21:27 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | SaleCommon Stock | 20,100 | $3.50 | $70,440.45 |
DisclosureSEC source: 0001209191-17-005511 · doc4.xml · nonDerivative · entry 2 Murphy Keith · CIK 0001536583 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,038,915 F1 · kind: The sale of shares was effectuated pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $3.50 to $3.515. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F4 · balance_after: This number does not include 1,831,454 shares of common stock underlying oustanding options and 30,000 shares of common stock underlying warrants held by Mr. Murphy; post-transaction Mr. Murphy continues to beneficially own or have a right to acquire 7,900,369 shares of common stock. Read SEC document |
| January 23, 2017 Filed Jan 25, 2017 21:27 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | SaleCommon Stock | 4,900 | $3.51 | $17,215.17 |
DisclosureSEC source: 0001209191-17-005511 · doc4.xml · nonDerivative · entry 1 Murphy Keith · CIK 0001536583 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,059,015 F1 · kind: The sale of shares was effectuated pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $3.50 to $3.54. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 14, 2016 Filed Dec 15, 2016 22:35 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | SaleCommon Stock | 50,000 | $3.72 | $185,955.00 |
DisclosureSEC source: 0001209191-16-155477 · doc4.xml · nonDerivative · entry 1 Murphy Keith · CIK 0001536583 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,063,915 F1 · kind: The sale of shares was effectuated pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $3.65 to $3.80. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: This number does not include 1,831,454 shares of common stock underlying oustanding options and 30,000 shares of common stock underlying warrants held by Mr. Murphy; post-transaction Mr. Murphy continues to beneficially own or have a right to acquire 7,925,369 shares of common stock. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 22:08 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 7,200 | $3.26 | $23,467.68 |
DisclosureSEC source: 0001209191-16-151275 · doc4.xml · nonDerivative · entry 1 Murphy Keith · CIK 0001536583 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,113,915 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1,831,454 shares of common stock underlying oustanding options and 30,000 shares of common stock underlying warrants held by Mr. Murphy; post-transaction Mr. Murphy continues to beneficially own or have a right to acquire 7,975,369 shares of common stock. Read SEC document |
| September 16, 2016 Filed Sep 20, 2016 21:02 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 1,394 | $4.00 | $5,576.00 |
DisclosureSEC source: 0001209191-16-142170 · doc4.xml · nonDerivative · entry 1 Murphy Keith · CIK 0001536583 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,121,115 F1 · shares: The reported transaction represents the mandatory withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the partial vesting and settlement of restricted stock units granted in July 2016. F2 · balance_after: This number does not include 1,831,454 shares of common stock underlying oustanding options and 30,000 shares of common stock underlying warrants held by Mr. Murphy; post-transaction Mr. Murphy continues to beneficially own or have a right to acquire 7,982,569 shares of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.